| Name | Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Lenses, Intraocular | 12 | 2023 | 138 | 5.800 |
Why?
|
| Corneal Diseases | 24 | 2023 | 536 | 4.960 |
Why?
|
| Lens Implantation, Intraocular | 15 | 2024 | 190 | 4.450 |
Why?
|
| Cornea | 31 | 2023 | 1326 | 3.930 |
Why?
|
| Keratoconus | 11 | 2023 | 110 | 3.810 |
Why?
|
| Fuchs' Endothelial Dystrophy | 7 | 2024 | 100 | 3.730 |
Why?
|
| Corneal Transplantation | 13 | 2022 | 321 | 3.710 |
Why?
|
| Descemet Stripping Endothelial Keratoplasty | 11 | 2024 | 111 | 3.560 |
Why?
|
| Descemet Membrane | 7 | 2021 | 71 | 3.300 |
Why?
|
| Cataract | 12 | 2023 | 827 | 2.940 |
Why?
|
| Phacoemulsification | 9 | 2020 | 149 | 2.500 |
Why?
|
| Keratomileusis, Laser In Situ | 10 | 2014 | 84 | 2.440 |
Why?
|
| Visual Acuity | 33 | 2024 | 2642 | 2.390 |
Why?
|
| Sclera | 6 | 2021 | 190 | 2.210 |
Why?
|
| Corneal Edema | 5 | 2024 | 47 | 2.090 |
Why?
|
| Refraction, Ocular | 5 | 2019 | 179 | 1.940 |
Why?
|
| Astigmatism | 8 | 2019 | 68 | 1.930 |
Why?
|
| Cataract Extraction | 10 | 2023 | 465 | 1.850 |
Why?
|
| Mucopolysaccharidosis I | 4 | 2022 | 52 | 1.600 |
Why?
|
| Corneal Topography | 10 | 2023 | 68 | 1.580 |
Why?
|
| Erythema | 2 | 2023 | 262 | 1.560 |
Why?
|
| Iris | 6 | 2023 | 231 | 1.500 |
Why?
|
| Corneal Ulcer | 7 | 2023 | 128 | 1.480 |
Why?
|
| Trigeminal Nerve Diseases | 2 | 2021 | 49 | 1.460 |
Why?
|
| Prostheses and Implants | 9 | 2022 | 1270 | 1.420 |
Why?
|
| Refractive Surgical Procedures | 3 | 2019 | 22 | 1.350 |
Why?
|
| Nerve Transfer | 2 | 2021 | 125 | 1.350 |
Why?
|
| Eye | 2 | 2023 | 710 | 1.300 |
Why?
|
| Intraoperative Complications | 4 | 2024 | 1184 | 1.270 |
Why?
|
| Artificial Organs | 4 | 2016 | 149 | 1.250 |
Why?
|
| Lasers, Excimer | 6 | 2015 | 69 | 1.190 |
Why?
|
| Eye Diseases | 3 | 2023 | 651 | 1.160 |
Why?
|
| Anterior Eye Segment | 4 | 2012 | 141 | 1.130 |
Why?
|
| Corneal Opacity | 4 | 2015 | 47 | 1.100 |
Why?
|
| Myopia | 9 | 2010 | 245 | 1.060 |
Why?
|
| Keratitis | 6 | 2012 | 239 | 1.050 |
Why?
|
| Hyperopia | 3 | 2019 | 41 | 1.040 |
Why?
|
| Eye Infections, Fungal | 5 | 2014 | 100 | 1.020 |
Why?
|
| Lens Subluxation | 2 | 2016 | 23 | 0.970 |
Why?
|
| Ophthalmology | 5 | 2023 | 549 | 0.930 |
Why?
|
| Coloboma | 2 | 2023 | 59 | 0.920 |
Why?
|
| Presbyopia | 2 | 2016 | 10 | 0.910 |
Why?
|
| Eye Infections, Bacterial | 6 | 2014 | 239 | 0.910 |
Why?
|
| Corneal Stroma | 6 | 2020 | 171 | 0.890 |
Why?
|
| Pseudophakia | 3 | 2021 | 60 | 0.880 |
Why?
|
| Corneal Wavefront Aberration | 2 | 2013 | 7 | 0.860 |
Why?
|
| Aberrometry | 2 | 2013 | 7 | 0.850 |
Why?
|
| Iris Diseases | 1 | 2023 | 37 | 0.840 |
Why?
|
| Smallpox | 1 | 2023 | 43 | 0.840 |
Why?
|
| Mucopolysaccharidoses | 2 | 2022 | 27 | 0.830 |
Why?
|
| Vaccinia | 1 | 2023 | 71 | 0.830 |
Why?
|
| Postoperative Complications | 15 | 2021 | 15638 | 0.820 |
Why?
|
| Suture Techniques | 6 | 2021 | 788 | 0.790 |
Why?
|
| Vision Disorders | 6 | 2016 | 1084 | 0.770 |
Why?
|
| Eye Injuries | 5 | 2023 | 227 | 0.740 |
Why?
|
| beta-Alanine | 1 | 2021 | 81 | 0.740 |
Why?
|
| Contact Lenses | 2 | 2012 | 138 | 0.700 |
Why?
|
| Photorefractive Keratectomy | 3 | 2008 | 38 | 0.700 |
Why?
|
| Anterior Chamber | 5 | 2024 | 194 | 0.700 |
Why?
|
| Endothelium, Corneal | 4 | 2020 | 214 | 0.680 |
Why?
|
| Benzoates | 1 | 2021 | 211 | 0.680 |
Why?
|
| Sutures | 2 | 2021 | 293 | 0.660 |
Why?
|
| Eye Abnormalities | 2 | 2013 | 241 | 0.650 |
Why?
|
| Prosthesis Implantation | 6 | 2016 | 590 | 0.640 |
Why?
|
| Nausea | 1 | 2021 | 677 | 0.610 |
Why?
|
| Aphakia, Postcataract | 1 | 2017 | 52 | 0.580 |
Why?
|
| Uveal Neoplasms | 2 | 2017 | 341 | 0.570 |
Why?
|
| Tomography, Optical Coherence | 5 | 2024 | 2880 | 0.560 |
Why?
|
| Retinal Dystrophies | 1 | 2017 | 64 | 0.550 |
Why?
|
| Ectopia Lentis | 1 | 2016 | 20 | 0.550 |
Why?
|
| Prosthesis-Related Infections | 2 | 2012 | 486 | 0.550 |
Why?
|
| Keratoplasty, Penetrating | 7 | 2022 | 144 | 0.540 |
Why?
|
| Fluoroquinolones | 3 | 2011 | 308 | 0.530 |
Why?
|
| Lens, Crystalline | 4 | 2016 | 388 | 0.510 |
Why?
|
| Uveitis, Anterior | 2 | 2023 | 102 | 0.500 |
Why?
|
| Lens Capsule, Crystalline | 2 | 2013 | 39 | 0.500 |
Why?
|
| Eyeglasses | 1 | 2016 | 137 | 0.500 |
Why?
|
| Iridectomy | 1 | 2015 | 48 | 0.490 |
Why?
|
| Photophobia | 1 | 2015 | 71 | 0.480 |
Why?
|
| Uveitis | 2 | 2023 | 393 | 0.470 |
Why?
|
| Copper | 1 | 2017 | 366 | 0.470 |
Why?
|
| Diagnosis, Computer-Assisted | 1 | 2019 | 706 | 0.460 |
Why?
|
| Elastic Modulus | 6 | 2019 | 210 | 0.460 |
Why?
|
| Humans | 116 | 2024 | 758381 | 0.450 |
Why?
|
| Blindness | 2 | 2015 | 582 | 0.450 |
Why?
|
| Headache | 1 | 2021 | 1248 | 0.430 |
Why?
|
| Posterior Eye Segment | 1 | 2013 | 18 | 0.430 |
Why?
|
| Endophthalmitis | 2 | 2014 | 257 | 0.430 |
Why?
|
| Corneal Surgery, Laser | 1 | 2012 | 11 | 0.420 |
Why?
|
| Optics and Photonics | 1 | 2014 | 304 | 0.420 |
Why?
|
| Cosmetic Techniques | 2 | 2012 | 148 | 0.410 |
Why?
|
| Coloring Agents | 1 | 2015 | 560 | 0.410 |
Why?
|
| Alcaligenes | 1 | 2011 | 1 | 0.400 |
Why?
|
| Glaucoma | 3 | 2022 | 1182 | 0.390 |
Why?
|
| Conjunctiva | 4 | 2011 | 479 | 0.380 |
Why?
|
| Accommodation, Ocular | 2 | 2016 | 47 | 0.370 |
Why?
|
| Lasers, Solid-State | 2 | 2010 | 175 | 0.370 |
Why?
|
| Graft Survival | 3 | 2020 | 3794 | 0.360 |
Why?
|
| Aspergillosis | 1 | 2012 | 243 | 0.350 |
Why?
|
| Physical Examination | 1 | 2016 | 1244 | 0.350 |
Why?
|
| Keratotomy, Radial | 1 | 2009 | 3 | 0.350 |
Why?
|
| Gram-Negative Bacterial Infections | 2 | 2011 | 237 | 0.350 |
Why?
|
| Glaucoma, Angle-Closure | 1 | 2012 | 191 | 0.350 |
Why?
|
| Anesthesia | 1 | 2021 | 1582 | 0.350 |
Why?
|
| Ocular Hypertension | 2 | 2008 | 206 | 0.340 |
Why?
|
| Prosthesis Fitting | 1 | 2010 | 75 | 0.340 |
Why?
|
| Dry Eye Syndromes | 1 | 2014 | 385 | 0.340 |
Why?
|
| Acanthamoeba Keratitis | 2 | 2007 | 12 | 0.330 |
Why?
|
| Sensation Disorders | 1 | 2010 | 160 | 0.320 |
Why?
|
| Cell Count | 3 | 2020 | 1835 | 0.320 |
Why?
|
| Keratitis, Herpetic | 1 | 2009 | 77 | 0.320 |
Why?
|
| Ketorolac Tromethamine | 2 | 2006 | 21 | 0.310 |
Why?
|
| Mycobacterium chelonae | 1 | 2007 | 12 | 0.300 |
Why?
|
| Ophthalmic Solutions | 4 | 2021 | 304 | 0.290 |
Why?
|
| Virus Activation | 1 | 2009 | 319 | 0.280 |
Why?
|
| Epithelium, Corneal | 3 | 2023 | 249 | 0.280 |
Why?
|
| Scleritis | 1 | 2007 | 96 | 0.280 |
Why?
|
| Retrospective Studies | 23 | 2023 | 80170 | 0.270 |
Why?
|
| Iatrogenic Disease | 1 | 2009 | 538 | 0.270 |
Why?
|
| Wounds, Nonpenetrating | 1 | 2013 | 793 | 0.270 |
Why?
|
| Prednisolone | 5 | 2009 | 326 | 0.270 |
Why?
|
| Monkeypox virus | 2 | 2023 | 42 | 0.260 |
Why?
|
| Developing Countries | 3 | 2015 | 2866 | 0.260 |
Why?
|
| Drug Resistance, Bacterial | 3 | 2008 | 1055 | 0.250 |
Why?
|
| Protein Kinase Inhibitors | 1 | 2021 | 5629 | 0.240 |
Why?
|
| Reoperation | 4 | 2020 | 4282 | 0.240 |
Why?
|
| Middle Aged | 32 | 2021 | 219560 | 0.230 |
Why?
|
| Optic Nerve Diseases | 1 | 2008 | 342 | 0.230 |
Why?
|
| Male | 41 | 2023 | 358742 | 0.220 |
Why?
|
| Herpesvirus 1, Human | 1 | 2009 | 753 | 0.220 |
Why?
|
| Eye Infections | 1 | 2004 | 62 | 0.220 |
Why?
|
| Capsulorhexis | 1 | 2023 | 12 | 0.220 |
Why?
|
| Aqueous Humor | 1 | 2024 | 153 | 0.220 |
Why?
|
| Mass Screening | 1 | 2019 | 5425 | 0.220 |
Why?
|
| Postoperative Care | 1 | 2010 | 1471 | 0.220 |
Why?
|
| Abnormalities, Multiple | 1 | 2010 | 1414 | 0.210 |
Why?
|
| Scleral Diseases | 2 | 2002 | 22 | 0.200 |
Why?
|
| Anti-Inflammatory Agents, Non-Steroidal | 2 | 2006 | 2270 | 0.200 |
Why?
|
| Female | 41 | 2024 | 390316 | 0.200 |
Why?
|
| Eye Burns | 1 | 2002 | 65 | 0.200 |
Why?
|
| Eye Neoplasms | 3 | 2010 | 306 | 0.200 |
Why?
|
| Device Removal | 3 | 2012 | 633 | 0.200 |
Why?
|
| Prosthesis Design | 4 | 2021 | 2105 | 0.190 |
Why?
|
| Treatment Outcome | 15 | 2022 | 64379 | 0.190 |
Why?
|
| Polypropylenes | 1 | 2021 | 63 | 0.190 |
Why?
|
| Glaucoma Drainage Implants | 1 | 2022 | 106 | 0.190 |
Why?
|
| Aged | 18 | 2024 | 168217 | 0.180 |
Why?
|
| Microscopy, Confocal | 4 | 2016 | 1969 | 0.180 |
Why?
|
| Tonometry, Ocular | 1 | 2021 | 235 | 0.180 |
Why?
|
| Keratoconjunctivitis | 2 | 1998 | 40 | 0.180 |
Why?
|
| Lacerations | 1 | 2002 | 148 | 0.170 |
Why?
|
| Decision Support Techniques | 1 | 2010 | 1996 | 0.170 |
Why?
|
| Drug Therapy, Combination | 5 | 2012 | 6293 | 0.170 |
Why?
|
| rho-Associated Kinases | 1 | 2021 | 280 | 0.170 |
Why?
|
| Rupture, Spontaneous | 2 | 2013 | 353 | 0.160 |
Why?
|
| Intraocular Pressure | 3 | 2022 | 1288 | 0.160 |
Why?
|
| Adult | 27 | 2023 | 219916 | 0.160 |
Why?
|
| Learning Curve | 1 | 2020 | 231 | 0.150 |
Why?
|
| Ciliary Body | 2 | 1997 | 166 | 0.150 |
Why?
|
| Capsule Opacification | 1 | 2017 | 2 | 0.150 |
Why?
|
| Surgical Wound Infection | 1 | 2007 | 1526 | 0.150 |
Why?
|
| Models, Theoretical | 1 | 2010 | 3561 | 0.150 |
Why?
|
| Adenovirus Infections, Human | 1 | 1998 | 73 | 0.150 |
Why?
|
| Anesthesia, Local | 1 | 2000 | 276 | 0.140 |
Why?
|
| Anti-Bacterial Agents | 5 | 2011 | 7403 | 0.140 |
Why?
|
| Eye Infections, Viral | 1 | 1998 | 60 | 0.140 |
Why?
|
| Spectrum Analysis | 1 | 2019 | 451 | 0.140 |
Why?
|
| Burns, Chemical | 1 | 2018 | 122 | 0.140 |
Why?
|
| Health Care Costs | 1 | 2010 | 3245 | 0.140 |
Why?
|
| Acute Disease | 2 | 2021 | 7225 | 0.140 |
Why?
|
| Diagnostic Techniques, Ophthalmological | 1 | 2019 | 250 | 0.140 |
Why?
|
| Choroid Neoplasms | 1 | 1998 | 177 | 0.140 |
Why?
|
| Adjuvants, Pharmaceutic | 1 | 1996 | 48 | 0.130 |
Why?
|
| Drug Implants | 1 | 2016 | 230 | 0.130 |
Why?
|
| Hot Temperature | 1 | 2002 | 1434 | 0.130 |
Why?
|
| Glare | 1 | 2015 | 6 | 0.130 |
Why?
|
| Elasticity | 2 | 2015 | 652 | 0.130 |
Why?
|
| Cysts | 1 | 2020 | 681 | 0.120 |
Why?
|
| Glaucoma, Open-Angle | 2 | 2021 | 734 | 0.120 |
Why?
|
| Wounds, Penetrating | 1 | 1997 | 306 | 0.120 |
Why?
|
| Patient Satisfaction | 2 | 2018 | 3446 | 0.120 |
Why?
|
| Axial Length, Eye | 1 | 2014 | 33 | 0.120 |
Why?
|
| Intravitreal Injections | 1 | 2016 | 384 | 0.120 |
Why?
|
| Pigmentation | 1 | 2015 | 144 | 0.120 |
Why?
|
| Homosexuality, Male | 1 | 2023 | 1329 | 0.120 |
Why?
|
| Melanoma, Experimental | 1 | 1998 | 559 | 0.120 |
Why?
|
| Antibiotic Prophylaxis | 2 | 2014 | 642 | 0.120 |
Why?
|
| Retinal Diseases | 2 | 2018 | 702 | 0.120 |
Why?
|
| Air | 2 | 2013 | 186 | 0.120 |
Why?
|
| Follow-Up Studies | 8 | 2022 | 39060 | 0.110 |
Why?
|
| Bioartificial Organs | 1 | 2014 | 47 | 0.110 |
Why?
|
| Collagen | 2 | 2013 | 2635 | 0.110 |
Why?
|
| Vitrectomy | 1 | 2016 | 391 | 0.110 |
Why?
|
| Cogan Syndrome | 1 | 2013 | 10 | 0.110 |
Why?
|
| Crystallins | 1 | 1993 | 75 | 0.110 |
Why?
|
| Disease Outbreaks | 1 | 2023 | 1755 | 0.110 |
Why?
|
| Endotamponade | 1 | 2013 | 37 | 0.110 |
Why?
|
| Apraxias | 1 | 2013 | 59 | 0.100 |
Why?
|
| Blepharitis | 2 | 2005 | 35 | 0.100 |
Why?
|
| Silicone Elastomers | 1 | 2012 | 78 | 0.100 |
Why?
|
| Trichosporon | 1 | 2012 | 9 | 0.100 |
Why?
|
| Lacrimal Apparatus | 1 | 2014 | 223 | 0.100 |
Why?
|
| Corneal Endothelial Cell Loss | 1 | 2012 | 25 | 0.100 |
Why?
|
| Standard of Care | 1 | 2016 | 550 | 0.100 |
Why?
|
| Lupus Erythematosus, Discoid | 2 | 2005 | 61 | 0.100 |
Why?
|
| Aza Compounds | 1 | 2011 | 34 | 0.100 |
Why?
|
| Intraoperative Period | 1 | 2012 | 512 | 0.100 |
Why?
|
| Tissue Donors | 1 | 2021 | 2311 | 0.090 |
Why?
|
| Wound Healing | 1 | 2002 | 2783 | 0.090 |
Why?
|
| Conjunctivitis | 2 | 2005 | 155 | 0.090 |
Why?
|
| Ophthalmologic Surgical Procedures | 2 | 2007 | 353 | 0.090 |
Why?
|
| Biometry | 1 | 2014 | 559 | 0.090 |
Why?
|
| Microbial Sensitivity Tests | 3 | 2008 | 1945 | 0.090 |
Why?
|
| Refractive Errors | 1 | 2013 | 145 | 0.090 |
Why?
|
| Cross-Linking Reagents | 2 | 2013 | 685 | 0.090 |
Why?
|
| Aspergillus fumigatus | 1 | 2012 | 156 | 0.090 |
Why?
|
| Immunoenzyme Techniques | 2 | 2010 | 1705 | 0.090 |
Why?
|
| Pilot Projects | 2 | 2021 | 8554 | 0.090 |
Why?
|
| Histone Deacetylase Inhibitors | 1 | 2016 | 772 | 0.090 |
Why?
|
| Diagnostic Tests, Routine | 1 | 2016 | 787 | 0.090 |
Why?
|
| Sudan | 1 | 2010 | 86 | 0.090 |
Why?
|
| Polymethyl Methacrylate | 1 | 2011 | 131 | 0.090 |
Why?
|
| Stromal Cells | 1 | 2016 | 1326 | 0.090 |
Why?
|
| Retinoblastoma | 1 | 1993 | 317 | 0.090 |
Why?
|
| Program Development | 1 | 2016 | 1297 | 0.090 |
Why?
|
| Microscopy | 2 | 2020 | 884 | 0.090 |
Why?
|
| Glucocorticoids | 3 | 2009 | 2144 | 0.090 |
Why?
|
| Neurilemmoma | 1 | 1995 | 523 | 0.090 |
Why?
|
| Epithelial Cells | 1 | 2002 | 3665 | 0.090 |
Why?
|
| Goldenhar Syndrome | 1 | 2010 | 39 | 0.080 |
Why?
|
| Curriculum | 1 | 2023 | 3717 | 0.080 |
Why?
|
| Antifungal Agents | 2 | 2012 | 749 | 0.080 |
Why?
|
| Vimentin | 1 | 2010 | 255 | 0.080 |
Why?
|
| Anti-Inflammatory Agents | 3 | 2018 | 1793 | 0.080 |
Why?
|
| Elasticity Imaging Techniques | 1 | 2014 | 388 | 0.080 |
Why?
|
| Retina | 2 | 2018 | 2637 | 0.080 |
Why?
|
| Visually Impaired Persons | 1 | 2010 | 78 | 0.080 |
Why?
|
| Autoimmune Diseases | 1 | 2021 | 2244 | 0.080 |
Why?
|
| Dermoid Cyst | 1 | 2010 | 92 | 0.080 |
Why?
|
| Sickness Impact Profile | 1 | 2010 | 298 | 0.080 |
Why?
|
| Finland | 1 | 2010 | 603 | 0.080 |
Why?
|
| Mycoses | 2 | 2007 | 386 | 0.080 |
Why?
|
| Keratins | 1 | 2010 | 497 | 0.080 |
Why?
|
| Acyclovir | 1 | 2009 | 268 | 0.080 |
Why?
|
| Titanium | 1 | 2011 | 484 | 0.080 |
Why?
|
| Ethiopia | 1 | 2010 | 462 | 0.080 |
Why?
|
| Surgical Flaps | 2 | 2007 | 1669 | 0.080 |
Why?
|
| Benzamidines | 1 | 2007 | 20 | 0.080 |
Why?
|
| Graft Rejection | 1 | 2021 | 4426 | 0.080 |
Why?
|
| Chloramphenicol | 1 | 2007 | 71 | 0.070 |
Why?
|
| Biguanides | 1 | 2007 | 21 | 0.070 |
Why?
|
| Education, Medical, Graduate | 1 | 2020 | 2359 | 0.070 |
Why?
|
| Alternaria | 1 | 2007 | 42 | 0.070 |
Why?
|
| Postoperative Period | 1 | 2012 | 1812 | 0.070 |
Why?
|
| Eyelids | 1 | 2010 | 277 | 0.070 |
Why?
|
| Aniridia | 1 | 2007 | 36 | 0.070 |
Why?
|
| Corneal Neovascularization | 1 | 2009 | 185 | 0.070 |
Why?
|
| Clarithromycin | 1 | 2007 | 85 | 0.070 |
Why?
|
| Aged, 80 and over | 5 | 2021 | 58681 | 0.070 |
Why?
|
| Patient Selection | 1 | 2019 | 4244 | 0.070 |
Why?
|
| Papilledema | 1 | 2008 | 130 | 0.070 |
Why?
|
| Quinolines | 1 | 2011 | 759 | 0.070 |
Why?
|
| Models, Economic | 1 | 2010 | 715 | 0.070 |
Why?
|
| Photosensitizing Agents | 1 | 2010 | 618 | 0.070 |
Why?
|
| Disease Management | 1 | 2016 | 2500 | 0.060 |
Why?
|
| Body Weights and Measures | 1 | 2006 | 208 | 0.060 |
Why?
|
| India | 1 | 2012 | 2329 | 0.060 |
Why?
|
| Ultraviolet Rays | 1 | 2010 | 1076 | 0.060 |
Why?
|
| Transplantation, Autologous | 1 | 2010 | 2114 | 0.060 |
Why?
|
| Costs and Cost Analysis | 1 | 2010 | 1673 | 0.060 |
Why?
|
| Prospective Studies | 4 | 2021 | 54136 | 0.060 |
Why?
|
| Photochemotherapy | 1 | 2010 | 819 | 0.060 |
Why?
|
| Syndrome | 1 | 2010 | 3262 | 0.060 |
Why?
|
| Quality-Adjusted Life Years | 1 | 2010 | 1722 | 0.060 |
Why?
|
| Electrocoagulation | 1 | 2004 | 152 | 0.050 |
Why?
|
| Disease Models, Animal | 3 | 2013 | 18125 | 0.050 |
Why?
|
| Health Care Surveys | 1 | 2010 | 2432 | 0.050 |
Why?
|
| Isoindoles | 1 | 2022 | 35 | 0.050 |
Why?
|
| Trifluridine | 1 | 2022 | 28 | 0.050 |
Why?
|
| Health Services Research | 1 | 2010 | 1812 | 0.050 |
Why?
|
| Antiviral Agents | 2 | 2009 | 3056 | 0.050 |
Why?
|
| Down Syndrome | 1 | 2010 | 892 | 0.050 |
Why?
|
| Adolescent | 6 | 2016 | 87888 | 0.050 |
Why?
|
| Drug Resistance, Neoplasm | 1 | 2016 | 5248 | 0.050 |
Why?
|
| Activities of Daily Living | 1 | 2010 | 2414 | 0.050 |
Why?
|
| Retrobulbar Hemorrhage | 1 | 2000 | 10 | 0.040 |
Why?
|
| Eye Injuries, Penetrating | 1 | 2002 | 121 | 0.040 |
Why?
|
| Child, Preschool | 5 | 2010 | 42058 | 0.040 |
Why?
|
| Anti-Infective Agents | 1 | 2007 | 981 | 0.040 |
Why?
|
| Aging | 2 | 2016 | 8651 | 0.040 |
Why?
|
| Disease Progression | 2 | 2014 | 13468 | 0.040 |
Why?
|
| Stress, Mechanical | 2 | 2016 | 1664 | 0.040 |
Why?
|
| Fundus Oculi | 2 | 1998 | 541 | 0.040 |
Why?
|
| Angiogenesis Inhibitors | 1 | 2009 | 2047 | 0.040 |
Why?
|
| Optic Nerve Injuries | 1 | 2000 | 147 | 0.040 |
Why?
|
| Prognosis | 3 | 2007 | 29558 | 0.040 |
Why?
|
| Ultrasonography | 2 | 2006 | 5952 | 0.040 |
Why?
|
| Sclerostomy | 1 | 1998 | 16 | 0.040 |
Why?
|
| Combined Modality Therapy | 2 | 2007 | 8530 | 0.040 |
Why?
|
| Tromethamine | 1 | 1997 | 31 | 0.040 |
Why?
|
| Tolmetin | 1 | 1997 | 24 | 0.040 |
Why?
|
| Tumor Cells, Cultured | 2 | 1998 | 6127 | 0.040 |
Why?
|
| Child | 6 | 2020 | 79813 | 0.040 |
Why?
|
| Carbonic Anhydrase Inhibitors | 1 | 2018 | 91 | 0.040 |
Why?
|
| Occlusive Dressings | 1 | 1997 | 52 | 0.040 |
Why?
|
| Benzamides | 1 | 2023 | 1368 | 0.040 |
Why?
|
| Cost-Benefit Analysis | 1 | 2010 | 5484 | 0.040 |
Why?
|
| Injections | 1 | 2000 | 830 | 0.030 |
Why?
|
| Amyloid beta-Peptides | 1 | 2010 | 3826 | 0.030 |
Why?
|
| Laser Therapy | 1 | 2004 | 1089 | 0.030 |
Why?
|
| Ultrasonography, Doppler, Color | 1 | 1998 | 231 | 0.030 |
Why?
|
| Risk Factors | 3 | 2022 | 73806 | 0.030 |
Why?
|
| Orbit | 1 | 2000 | 446 | 0.030 |
Why?
|
| ROC Curve | 1 | 2023 | 3563 | 0.030 |
Why?
|
| History, 20th Century | 1 | 2004 | 2772 | 0.030 |
Why?
|
| Oculomotor Muscles | 1 | 2000 | 407 | 0.030 |
Why?
|
| Phlebitis | 1 | 1995 | 35 | 0.030 |
Why?
|
| Incidence | 4 | 2022 | 21273 | 0.030 |
Why?
|
| Retinal Vein | 1 | 1995 | 47 | 0.030 |
Why?
|
| Imaging, Three-Dimensional | 3 | 2014 | 4048 | 0.030 |
Why?
|
| Central Nervous System Diseases | 1 | 2000 | 520 | 0.030 |
Why?
|
| Fluorescein Angiography | 2 | 1998 | 1044 | 0.030 |
Why?
|
| Gonioscopy | 1 | 1995 | 155 | 0.030 |
Why?
|
| Tissue Culture Techniques | 1 | 2016 | 290 | 0.030 |
Why?
|
| United States | 4 | 2022 | 72140 | 0.030 |
Why?
|
| Rabbits | 2 | 1998 | 4771 | 0.030 |
Why?
|
| Pressure | 1 | 1997 | 1155 | 0.030 |
Why?
|
| Administration, Topical | 2 | 2009 | 697 | 0.030 |
Why?
|
| Paraneoplastic Syndromes | 1 | 1995 | 155 | 0.030 |
Why?
|
| Dose-Response Relationship, Drug | 1 | 2006 | 10747 | 0.030 |
Why?
|
| Infant | 4 | 2010 | 36054 | 0.030 |
Why?
|
| Antineoplastic Agents | 1 | 2016 | 13591 | 0.030 |
Why?
|
| Anesthetics, Local | 1 | 2000 | 1000 | 0.030 |
Why?
|
| Antibodies, Monoclonal | 1 | 2009 | 9160 | 0.020 |
Why?
|
| Pigmentation Disorders | 1 | 1992 | 105 | 0.020 |
Why?
|
| Microscopy, Electron | 1 | 1995 | 2557 | 0.020 |
Why?
|
| Severity of Illness Index | 1 | 2009 | 15785 | 0.020 |
Why?
|
| Macaca | 1 | 1993 | 409 | 0.020 |
Why?
|
| Lung Neoplasms | 1 | 2016 | 13245 | 0.020 |
Why?
|
| Blotting, Northern | 1 | 1993 | 1543 | 0.020 |
Why?
|
| Neuroprotective Agents | 1 | 2018 | 955 | 0.020 |
Why?
|
| Animals | 8 | 2016 | 167777 | 0.020 |
Why?
|
| Epithelial-Mesenchymal Transition | 1 | 2016 | 730 | 0.020 |
Why?
|
| Fibrosis | 1 | 1998 | 2038 | 0.020 |
Why?
|
| Demography | 1 | 2015 | 1651 | 0.020 |
Why?
|
| Riboflavin | 1 | 2010 | 105 | 0.020 |
Why?
|
| Neoplasm Invasiveness | 1 | 1998 | 3617 | 0.020 |
Why?
|
| China | 1 | 2015 | 2337 | 0.020 |
Why?
|
| Protein Structure, Quaternary | 1 | 2010 | 428 | 0.020 |
Why?
|
| Epinephrine | 1 | 1992 | 790 | 0.020 |
Why?
|
| Alzheimer Disease | 1 | 2010 | 8544 | 0.020 |
Why?
|
| Steroids | 1 | 1994 | 926 | 0.020 |
Why?
|
| Scattering, Radiation | 1 | 2010 | 488 | 0.020 |
Why?
|
| Hydroxychloroquine | 2 | 2005 | 426 | 0.020 |
Why?
|
| Polymyxin B | 1 | 2007 | 44 | 0.020 |
Why?
|
| Trimethoprim | 1 | 2007 | 83 | 0.020 |
Why?
|
| Ofloxacin | 1 | 2007 | 66 | 0.020 |
Why?
|
| Itraconazole | 1 | 2007 | 43 | 0.020 |
Why?
|
| Cefazolin | 1 | 2008 | 94 | 0.020 |
Why?
|
| Xenograft Model Antitumor Assays | 1 | 2016 | 3574 | 0.020 |
Why?
|
| Practice Guidelines as Topic | 1 | 2005 | 7377 | 0.020 |
Why?
|
| Amphotericin B | 1 | 2007 | 142 | 0.020 |
Why?
|
| Biopsy | 2 | 1999 | 6768 | 0.020 |
Why?
|
| Gentamicins | 1 | 2008 | 251 | 0.020 |
Why?
|
| Eye Proteins | 1 | 2010 | 633 | 0.020 |
Why?
|
| Tumor Necrosis Factor-alpha | 1 | 2018 | 4342 | 0.020 |
Why?
|
| Ciprofloxacin | 1 | 2008 | 312 | 0.020 |
Why?
|
| Cattle | 1 | 2012 | 3846 | 0.020 |
Why?
|
| Case-Control Studies | 1 | 2023 | 22031 | 0.020 |
Why?
|
| Gram-Positive Bacterial Infections | 1 | 2008 | 343 | 0.020 |
Why?
|
| Debridement | 1 | 2007 | 492 | 0.020 |
Why?
|
| Prevalence | 1 | 2021 | 15646 | 0.010 |
Why?
|
| Reproducibility of Results | 2 | 2013 | 20052 | 0.010 |
Why?
|
| Light | 1 | 2010 | 1345 | 0.010 |
Why?
|
| Radiography | 1 | 1995 | 6955 | 0.010 |
Why?
|
| Brain | 1 | 2010 | 26951 | 0.010 |
Why?
|
| Double-Blind Method | 1 | 1997 | 12262 | 0.010 |
Why?
|
| Cytokines | 1 | 2018 | 7338 | 0.010 |
Why?
|
| Swine | 1 | 2013 | 5892 | 0.010 |
Why?
|
| Tumor Microenvironment | 1 | 2016 | 3840 | 0.010 |
Why?
|
| Time Factors | 4 | 2011 | 39873 | 0.010 |
Why?
|
| Pain | 1 | 1997 | 5065 | 0.010 |
Why?
|
| Young Adult | 3 | 2016 | 58808 | 0.010 |
Why?
|
| Multivariate Analysis | 1 | 2015 | 12096 | 0.010 |
Why?
|
| Drug Combinations | 1 | 2007 | 2020 | 0.010 |
Why?
|
| Bone Marrow Transplantation | 1 | 1989 | 2693 | 0.010 |
Why?
|
| Transplantation, Homologous | 1 | 2010 | 4809 | 0.010 |
Why?
|
| Neoplasm Staging | 1 | 2016 | 11152 | 0.010 |
Why?
|
| Electroretinography | 2 | 1995 | 517 | 0.010 |
Why?
|
| Logistic Models | 1 | 2015 | 13276 | 0.010 |
Why?
|
| Rupture | 1 | 2002 | 443 | 0.010 |
Why?
|
| Cross-Sectional Studies | 1 | 2021 | 25953 | 0.010 |
Why?
|
| Gene Expression | 1 | 1993 | 7583 | 0.010 |
Why?
|
| Mice, Inbred C57BL | 1 | 1998 | 22006 | 0.010 |
Why?
|
| Magnetic Resonance Imaging | 2 | 1997 | 36285 | 0.010 |
Why?
|
| Mice | 2 | 1998 | 81107 | 0.010 |
Why?
|
| Amino Acid Sequence | 1 | 2010 | 13447 | 0.010 |
Why?
|
| Vascular Endothelial Growth Factor A | 1 | 2009 | 3480 | 0.010 |
Why?
|
| Phenotype | 1 | 2016 | 16534 | 0.010 |
Why?
|
| RNA, Messenger | 1 | 1993 | 12760 | 0.010 |
Why?
|
| Chronic Disease | 2 | 2005 | 9266 | 0.010 |
Why?
|
| Molecular Sequence Data | 1 | 2010 | 17617 | 0.010 |
Why?
|
| Hypertrophy | 1 | 1999 | 555 | 0.010 |
Why?
|
| Melanoma | 1 | 1995 | 5691 | 0.010 |
Why?
|
| Radioisotopes | 1 | 1997 | 495 | 0.010 |
Why?
|
| Skin Neoplasms | 1 | 1995 | 5797 | 0.010 |
Why?
|
| Night Blindness | 1 | 1995 | 52 | 0.010 |
Why?
|
| Antirheumatic Agents | 1 | 2005 | 1368 | 0.010 |
Why?
|
| Diagnosis, Differential | 2 | 2005 | 12951 | 0.010 |
Why?
|
| Forecasting | 1 | 2004 | 2920 | 0.010 |
Why?
|
| Retinal Rod Photoreceptor Cells | 1 | 1995 | 200 | 0.010 |
Why?
|
| Uveal Diseases | 1 | 1992 | 45 | 0.010 |
Why?
|
| Prolapse | 1 | 1992 | 63 | 0.010 |
Why?
|
| Gadolinium | 1 | 1997 | 959 | 0.010 |
Why?
|
| Clinical Trials as Topic | 1 | 2004 | 7985 | 0.000 |
Why?
|
| Image Enhancement | 1 | 1997 | 2880 | 0.000 |
Why?
|
| Optic Nerve | 1 | 1989 | 567 | 0.000 |
Why?
|
| Edema | 1 | 1989 | 768 | 0.000 |
Why?
|